ClinicalTrials.gg
CompletedNCT02006121TOLEDOUpdated Jul 8, 2019Results posted

Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease

A Phase 3 interventional study of Apomorphine hydrochloride and Placebo in Parkinson's Disease, sponsored by Britannia Pharmaceuticals Ltd.. Completed at 20 sites in 7 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2019-07-08.

Sponsored by Britannia Pharmaceuticals Ltd. · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
107
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies testing apomorphine in Parkinson Disease — 1 open to participants now, 2 under way, 1 of them phase 3. Apomorphine · Parkinson Disease.

Enrollment
8th of 32
107 · median 42
Started
2014
with 1 other
Phase 3
12 of 32
none open now
Registered
15th of 32
by date
Lead sponsor
1 of 32
Britannia Pharmaceuticals Ltd.

Among the 32 studies testing apomorphine in Parkinson Disease, this one is the 8th largest by enrollment, is one of 2 that started in 2014, is one of 12 in phase 3, and was the 15th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 32 studies testing apomorphine in Parkinson Disease is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About apomorphine

Apomorphine: first FDA approval 2004 (APOKYN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing apomorphine in Parkinson Disease, or all of them as a file.
02

Study summary

The primary objective of the trial was to investigate the efficacy of apomorphine continuous subcutaneous infusion compared to placebo in Parkinson's Disease patients with motor fluctuations not well controlled on medical treatment.

The secondary objective of the study was to investigate the safety and tolerability of apomorphine continuous subcutaneous therapy.

Read the detailed description

The primary efficacy variable is the mean change in time spent "OFF" from baseline (start of blinded treatment) to the end of a 12 weeks' double-blind treatment period based on patient diaries. Patients recorded their motor symptoms in half-hour blocks as OFF, ON without dyskinesia, ON without troublesome dyskinesia, or sleeping using the Hauser Parkinson's Disease home diary.

Key secondary Endpoints (tested hierarchically):

  • Change in time spent "ON without troublesome dyskinesia"
  • Patient Global Impression of Change

Other Endpoints:

  • Percentage of patients with response to therapy, defined as a mean OFF time reduction of at least 2 hours
  • Change in oral levodopa and levodopa equivalent dose
03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • Parkinson's disease
  • motor fluctuations
  • not well controlled
  • medical treatment
  • apomorphine
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients aged ≥30 years
  • Diagnosis of idiopathic PD of >3 years' duration, defined by the UK Brain Bank criteria (with the exception of >1 affected relative being allowed), without any other known or suspected cause of Parkinsonism
  • Hoehn \& Yahr stage up to 3 in the ON and 2 to 5 in the OFF state
  • Motor fluctuations not adequately controlled on medical treatment including levodopa which was judged by the treating physician to be optimal
  • Average of OFF time > 3 hours/day based on screening and baseline diary entries with no day with \< 2 hours of OFF time recorded
  • Stable medication regimen, with a stable dose of levodopa administered in at least 4 intakes, for at least 28 days prior to baseline. All oral or transdermal antiparkinsonian drugs were permitted, with the exception of budipine. This regimen might include the use of levodopa/DDCI rescue medication, if this occurred up to 2 times a day, at doses of up to 200 mg levodopa/day
  • Patients must be able to differentiate between the ON and OFF state and between troublesome and non-troublesome dyskinesias
  • Male and female patients must be compliant with a highly effective method (oral hormonal contraception alone is not considered highly effective and must be used in combination with a barrier method) during the study and for the 12-month OLP, if sexually active
  • Females of must have a negative serum human chorionic gonadotropin (hCG) or urine pregnancy test at screening
  • Ability to accurately complete a paper diary on designated days (with assistance from caregivers, if required), recording periods when they are "ON without troublesome dyskinesia", "ON with troublesome dyskinesia", OFF, and sleeping
  • Written prior to enrolment, after being provided with detailed information about the nature, risks, and scope of the clinical trial as well as the expected desirable and adverse effects of the study treatments
  • Patients considered reliable and capable of adhering to the protocol, visit schedule, and medication intake according to the judgment of the investigator

Exclusion criteria

Exclusion Criteria:

  • History of respiratory depression
  • to apomorphine or any of the medicinal product
  • High suspicion of other parkinsonian syndromes
  • Presence of severe freezing or postural instability leading to falls during the ON state
  • Concomitant therapy or within 28 days prior to baseline with: apomorphine pen injections; alpha-methyl dopa, metoclopramide, reserpine, neuroleptics, methylphenidate, or amphetamine; intrajejunal levodopa
  • Previous use of apomorphine pump treatment
  • History of deep brain stimulation or lesional surgery for PD
  • Any medical condition that is likely to interfere with an adequate participation in the study, including e.g. current diagnosis of unstable epilepsy; clinically relevant cardiac dysfunction and/or myocardial infarction or stroke within the last 12 months
  • Symptomatic, clinically relevant and medically uncontrolled orthostatic hypotension
  • Patients with a borderline corrected for heart rate according to Bazett's formula (QTcB) of >450 msec for male and >470 msec for female at screening or history of long QT syndrome; or >450 msec absolute duration
  • Clinically relevant hepatic dysfunction (total >2.0 mg/dL, [ALT] and aspartate transaminase [AST] >2 times the )
  • Clinically relevant renal dysfunction (serum creatinine >2.0 mg/dL)
  • Pregnant and breastfeeding women
  • Clinically relevant cognitive decline, defined as ≤24 or according to (DSM) IV criteria for dementia
  • Active psychosis or history of at least moderate psychosis in the past year, or with medically uncontrolled severe depression; very mild illusions or hallucinations in the sense of "feelings of passage or presence" with fully retained insight are not an exclusion criterion
  • Known history of melanoma
  • Any therapy in the 4 weeks prior to randomization
  • History or current drug or alcohol abuse or dependencies
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
107 participants (actual)

Study arms

  • Active comparator
    Apomorphine hydrochloride

    Apo-go® Apomorphine hydrochloride 5 mg/ml solution for infusion in pre-filled syringe

    Drug: Apomorphine hydrochloride

  • Placebo comparator
    Placebo

    Placebo: saline infusion

    Drug: Placebo

Interventions

  • DrugApomorphineStudies of ApomorphineApomorphine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Apomorphine hydrochloride 5 mg/ml solution for infusion in pre-filled syringe

    Also known as: Apo-go

  • DrugPlacebo

    Sodium chloride 9 mg/ml

06

What researchers measure

Primary outcomes

  1. Mean Change in Daily OFF Time From Baseline (Start of Blinded Treatment) to the End of Double-blind Phase (Visit 10) Based on Patient Diaries Using MMRM mITT Population

    The least squares mean reduction (improvement) in OFF time as reported by the patient using the Hauser Parkinson's disease home diary. Patients categorised their motor symptoms into OFF, ON with dyskinesia, ON without troublesome dyskinesia or sleeping using half hour blocks over 24 hours. Daily OFF time was computed from the average of valid motor diaries from the two days preceding each visit. Correct diary completion was evaluated during screening and observed by the investigator to ensure patients could categorise their motor symptoms correctly. A diary was considered valid if no more than 4 half-hour periods were either absent or duplicated. There were no invalid diaries at Baseline or Week 12.

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Mean Change in Daily Time Spent "ON Without Troublesome Dyskinesia" From Baseline to the End of the Double-blind Phase (Visit 10), Based on Patient Diaries Using MMRM mITT Population

    The least squares mean change in "ON time without troublesome dyskinesia" as reported by the patient using the Hauser Parkinson's disease home diary. Each half hour of the day categorised as OFF, ON with dyskinesia, ON without troublesome dyskinesia or asleep. "ON time without troublesome dyskinesia" measures good ON time for a Parkinson's disease patient.

    Time frame: Baseline and 12 weeks

  2. Patient Global Impression of Change (PGIC), Using the mITT Population

    PGIC is a self-administered questionnaire measuring personal general state of health on a 7-point rating scale. The 7 ordinal categories from which patients must choose are 'very much improved', 'much improved', 'minimally improved', 'no change', 'minimally worse', 'much worse', and 'very much worse. Results are presented as the % of patients who reported at least minimal improvement in general health status at week 12 compared to Baseline. A Wilcoxon range sum test was performed to test for treatment differences from baseline to end of 12 weeks' treatment period.

    Time frame: Baseline and 12 weeks

  3. Mean Change in Oral Levodopa Dose From Baseline to Visit 10 Using MMRM for the mITT Population

    The least squares mean change in oral levodopa dose from Baseline to Visit 10 (week 12) was calculated excluding 3 centres who declined to participate in collecting the necessary details of PRN use of levodopa.

    Time frame: Baseline and 12 weeks

  4. Mean Change in Levodopa Equivalent Dose From Baseline to Visit 10 (Week 12) Using MMRM in the mITT Population

    Levodopa equivalent dose is an indication of the burden of medication taken to control symptoms of Parkinson's disease with all medications other than levodopa itself being converted to a calculated levodopa dose using the methodology published by Tomlinson et al, 2010. The computation of LED excludes the study drug.

    Time frame: Baseline and 12 weeks

07

Results

Posted Jul 8, 2019

Participant flow

Double Blind Phase
Participant flow — Double Blind Phase
MilestoneApomorphine HydrochloridePlacebo
Started5453
Completed4229
Not completed1224
Withdrew: Adverse event60
Withdrew: Lack of efficacy116
Withdrew: Withdrawal by subject34
Withdrew: Non-compliance with study drug13
Withdrew: Minimum infusion rate poorly tolerated10
Withdrew: Inconvenience of infusion system01
Open Label Phase
Participant flow — Open Label Phase
MilestoneApomorphine HydrochloridePlacebo
Started840
Completed590
Not completed250
Withdrew: Adverse event150
Withdrew: Lack of efficacy20
Withdrew: Protocol violation20
Withdrew: Withdrawal by subject30
Withdrew: Non-compliance with study drug30

Outcome measures

PrimaryMean Change in Daily OFF Time From Baseline (Start of Blinded Treatment) to the End of Double-blind Phase (Visit 10) Based on Patient Diaries Using MMRM mITT Population

The least squares mean reduction (improvement) in OFF time as reported by the patient using the Hauser Parkinson's disease home diary. Patients categorised their motor symptoms into OFF, ON with dyskinesia, ON without troublesome dyskinesia or sleeping using half hour blocks over 24 hours. Daily OFF time was computed from the average of valid motor diaries from the two days preceding each visit. Correct diary completion was evaluated during screening and observed by the investigator to ensure patients could categorise their motor symptoms correctly. A diary was considered valid if no more than 4 half-hour periods were either absent or duplicated. There were no invalid diaries at Baseline or Week 12.

Time frame:
Baseline and 12 weeks
Reported as:
Least squares mean · Hours
Mean Change in Daily OFF Time From Baseline (Start of Blinded Treatment) to the End of Double-blind Phase (Visit 10) Based on Patient Diaries Using MMRM mITT Population
HoursApomorphine HydrochloridePlacebo
Mean Change in Daily OFF Time From Baseline (Start of Blinded Treatment) to the End of Double-blind Phase (Visit 10) Based on Patient Diaries Using MMRM mITT Population-2.61 (-3.43 to -1.80)-0.75 (-1.66 to 0.16)
Statistical analysis
  • Apomorphine Hydrochloride vs Placebo · Mixed Models Analysis · p = 0.0047
SecondaryMean Change in Daily Time Spent "ON Without Troublesome Dyskinesia" From Baseline to the End of the Double-blind Phase (Visit 10), Based on Patient Diaries Using MMRM mITT Population

The least squares mean change in "ON time without troublesome dyskinesia" as reported by the patient using the Hauser Parkinson's disease home diary. Each half hour of the day categorised as OFF, ON with dyskinesia, ON without troublesome dyskinesia or asleep. "ON time without troublesome dyskinesia" measures good ON time for a Parkinson's disease patient.

Time frame:
Baseline and 12 weeks
Reported as:
Least squares mean · Hours
Mean Change in Daily Time Spent "ON Without Troublesome Dyskinesia" From Baseline to the End of the Double-blind Phase (Visit 10), Based on Patient Diaries Using MMRM mITT Population
HoursApomorphine HydrochloridePlacebo
Mean Change in Daily Time Spent "ON Without Troublesome Dyskinesia" From Baseline to the End of the Double-blind Phase (Visit 10), Based on Patient Diaries Using MMRM mITT Population2.90 (2.07 to 3.73)0.85 (-0.09 to 1.78)
Statistical analysis
  • Apomorphine Hydrochloride vs Placebo · Mixed Models Analysis · p = 0.0022
SecondaryPatient Global Impression of Change (PGIC), Using the mITT Population

PGIC is a self-administered questionnaire measuring personal general state of health on a 7-point rating scale. The 7 ordinal categories from which patients must choose are 'very much improved', 'much improved', 'minimally improved', 'no change', 'minimally worse', 'much worse', and 'very much worse. Results are presented as the % of patients who reported at least minimal improvement in general health status at week 12 compared to Baseline. A Wilcoxon range sum test was performed to test for treatment differences from baseline to end of 12 weeks' treatment period.

Time frame:
Baseline and 12 weeks
Reported as:
Number · % of participants
Patient Global Impression of Change (PGIC), Using the mITT Population
% of participantsApomorphine HydrochloridePlacebo
Patient Global Impression of Change (PGIC), Using the mITT Population79.123.5
Statistical analysis
  • Apomorphine Hydrochloride vs Placebo · Wilcoxon (Mann-Whitney) · p = <0.0001
SecondaryMean Change in Oral Levodopa Dose From Baseline to Visit 10 Using MMRM for the mITT Population

The least squares mean change in oral levodopa dose from Baseline to Visit 10 (week 12) was calculated excluding 3 centres who declined to participate in collecting the necessary details of PRN use of levodopa.

Time frame:
Baseline and 12 weeks
Reported as:
Least squares mean · mg
Mean Change in Oral Levodopa Dose From Baseline to Visit 10 Using MMRM for the mITT Population
mgApomorphine HydrochloridePlacebo
Mean Change in Oral Levodopa Dose From Baseline to Visit 10 Using MMRM for the mITT Population-242.09 (-346.58 to -137.61)-76.46 (-185.17 to 32.25)
Statistical analysis
  • Apomorphine Hydrochloride vs Placebo · Mixed Models Analysis · p = 0.005
SecondaryMean Change in Levodopa Equivalent Dose From Baseline to Visit 10 (Week 12) Using MMRM in the mITT Population

Levodopa equivalent dose is an indication of the burden of medication taken to control symptoms of Parkinson's disease with all medications other than levodopa itself being converted to a calculated levodopa dose using the methodology published by Tomlinson et al, 2010. The computation of LED excludes the study drug.

Time frame:
Baseline and 12 weeks
Reported as:
Least squares mean · mg
Mean Change in Levodopa Equivalent Dose From Baseline to Visit 10 (Week 12) Using MMRM in the mITT Population
mgApomorphine HydrochloridePlacebo
Mean Change in Levodopa Equivalent Dose From Baseline to Visit 10 (Week 12) Using MMRM in the mITT Population-502.02 (-626.45 to -377.60)-150.87 (-280.14 to -21.59)
Statistical analysis
  • Apomorphine Hydrochloride vs Placebo · Mixed Models Analysis · p = <0.0001

Adverse events

Collected over Adverse Events were collected during the double-blind and open label phases of the study. 98 patients were exposed to at least one dose of apomorphine with a cumulative person time of 4081 weeks of exposure. The range of exposure to apomorphine was 37-464 days (mean 397 days). In addition, 53 patients (44 of whom went onto apomorphine in the open label phase) were exposed to placebo treatment in the double blind phase with a maximum 12 weeks of exposure.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Apomorphine Hydrochloride0/98 (0%)23/98 (23.5%)94/98 (95.9%)
Placebo0/53 (0%)2/53 (3.8%)30/53 (56.6%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventApomorphine HydrochloridePlacebo
Infusion site cellulitisInfections and infestations2/980/53
FallInjury, poisoning and procedural complications2/980/53
DepressionPsychiatric disorders0/981/53
ColitisGastrointestinal disorders1/981/53
Confusional statePsychiatric disorders1/980/53
LymphopeniaBlood and lymphatic system disorders1/980/53
Myocardial infarctionCardiac disorders1/980/53
Eosinophil count decreasedInvestigations1/980/53
Haematocrit decreasedInvestigations1/980/53
Blood disorderBlood and lymphatic system disorders1/980/53
Most frequent other events
Showing 10 of 24
Most frequent other events
EventApomorphine HydrochloridePlacebo
Infusion site noduleGeneral disorders46/980/53
NauseaGastrointestinal disorders20/985/53
SomnolenceNervous system disorders19/982/53
Infusion site erythemaGeneral disorders15/982/53
DyskinesiaNervous system disorders14/980/53
InsomniaPsychiatric disorders13/981/53
DizzinessNervous system disorders11/982/53
HeadacheNervous system disorders10/982/53
Infusion site haematomaGeneral disorders8/985/53
VomitingGastrointestinal disorders8/982/53

Baseline characteristics

Demographic Characteristics displayed for mITT population

Age, Categorical
Age, Categorical(Participants)Apomorphine HydrochloridePlaceboTotal
<=18 years000
Between 18 and 65 years262854
>=65 years272451
Age, Continuous
Age, Continuous(years)Apomorphine HydrochloridePlaceboTotal
Mean63.58 ± 9.3263.00 ± 8.3263.29 ± 8.80
Sex: Female, Male
Sex: Female, Male(Participants)Apomorphine HydrochloridePlaceboTotal
Female192039
Male343266
08

Study locations

20 sites
  • Medizinische Universität Graz / Univ. Klinik für Neurologie
    Graz, Austria
  • Medizinische Universität Innsbruck
    Innsbruck, Austria
  • Donauspital / SMZ-Ost, Abteilung für Neurologie, Sekretariat (Stock 1, Ebene 4)
    Vienna, 1220, Austria
  • Bispebjerg University Hospital, Movement Disorder Centre
    Copenhagen, Denmark
  • CHRU Clermont- Ferrand Gabriel-Montpied
    Clermont-Ferrand Cedex 1, France
  • CHU de Rennes, Hôpital Pontchaillou
    Rennes Cedex 9, France
  • CHU Toulouse, Hôpital Purpan, Centre d'Investigation Clinique
    Toulouse Cedex 9, France
  • Neurologisches Fachkrankenhausfür Bewegungsstörungen / Parkinson
    Beelitz-Heilstätten, Germany
  • Klinikum Bremerhaven-Reinkenheide gGmbH, Neurologische Klinik
    Bremerhaven, Germany
  • Paracelsus Elena-Klinik Kassel
    Kassel, Germany
  • Schön Klinik München Schwabing / Neurologie und Klinische Neurophysiologie
    München, Germany
  • Universitair Medisch Centrum
    Groningen, Netherlands
  • Atrium MC parkstad
    Heerlen, Netherlands
  • Erasmus MC
    Rotterdam, Netherlands
  • Hospital Clínic de Barcelona
    Barcelona, Spain
  • Hospital Universitario Fundación Jiménez Díaz
    Madrid, Spain
  • The Walton Centre Nhs Foundation Trust
    Liverpool, United Kingdom
  • Kings College Hospital NHS Foundation Trust
    London, United Kingdom
  • St George's Heathcare NHS Trust
    London, United Kingdom
  • Newcastle University, Clinical Ageing Research Unit (CARU)
    Newcastle, United Kingdom
09

References and documents

Publications

  • Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Lockhart D, Staines H, Lees A. Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study. Parkinsonism Relat Disord. 2021 Feb;83:79-85. doi: 10.1016/j.parkreldis.2020.12.024. Epub 2021 Jan 12. PubMed 33486139 ↗
  • Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Spivey K, Vel S, Staines H, Lees A. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2018 Sep;17(9):749-759. doi: 10.1016/S1474-4422(18)30239-4. Epub 2018 Jul 25. PubMed 30055903 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Jun 2016, 27 months.

Results were first posted in Jul 2019, 3 years 1 month after primary completion.

Of 40 industry-sponsored phase 3 interventional studies under Parkinson Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 54. This study's 27 months is below that.

Counting every sponsor, half of 68 studies reached it within 35 months; a quarter within 22 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2013
First posted
Dec 9, 2013
StartActual
Mar 3, 2014
Primary completionActual
Jun 6, 2016
CompletionActual
Jun 8, 2017
Results first posted
Jul 8, 2019
Last update
Jul 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02006121
Lead sponsor
Britannia Pharmaceuticals Ltd.
Responsible party
Sponsor
First posted
Dec 9, 2013
Start date
Mar 3, 2014
Primary completion
Jun 6, 2016
Completion
Jun 8, 2017
Results posted
Jul 8, 2019
Last update
Jul 8, 2019

Study contacts

Regina Katzenschlager, Doz. Dr.
principal investigator · Donauspital KH SMZ Ost, Neurologie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apomorphine

Start the discussion